Autonomic pharmacology question set

8/18/2019 Autonomic pharmacology question set

1/130

!

!"#$%&'($)(*%+%,- %/

(#0%!%)1* !"$2%#3 3-30")

1!0$%4#*01%!

#$%& '()%*


2/130

+!"#$%

156789:;6 (:6858?7@8:A 3BA6>?

1C &>77EF 5>7@8:A ABA6>?AG ,- ./0*1%23 4/5$61*789 0/4(0(61: ;7(*1/&1$7(

?- (:6858?67@8:A ABA6>? H3!3I3 *6*1/0%2*5 A(@%6%1%/69 6/1 A(1(70%6(A

;8 167@8:A ABA6>? H&!3I3 *6*1/0%2*5 A(@%6%1%/6B- !85JE97>5>7K


3/130

B!"#$%

11C ,>5>7EF 87KE5


4/130

G!"#$%

/ OC


5/130

N!"#$%

111C *=8F7K5>7K*1/&1=*6=5%/6%2 6($7/6&

B- 48DE?7K*1/&1=*6=5%/6%2 6($7/6& 1/ 7(6*5 4*&2$5*1$7( &0//1< 0$&25(G- !7K*1*7*&80>*1/&1=*6=5%/6%2


6/130

Q!"#$%

12C !(!* ?>9(>1%A( V

CDJVF: /1(>1%A(&

E- DW3 7(5(*&(A @7/0 6%17(7=%2 6(74(&

2C !>7@> 6>7?


7/130X!"#$%

21C $>;>D687A 9 E;6 5>:7867E5A?7AL ;8J67E5A?7AE59 5>:78?89:FE687A D>77EF 5>7@8:A ABA6>?A ,- $>;>D687 A:P6BD>A

!- ?*&(A /6 7(5*1%4( *@@%6%1%(& C>/1(62%(&F @/7 *=/6%&1& /7 *61*=/6%&1&

/ RC


8/130Y!"#$%

?- (97>58;>D687A3 O%A(&>7(*A A%&17%;$1%/6

!- J(97>58;>D687A3 0(A%*1( 1%*- !3 &0//1< 0$&25(

;- +3 6(74( 1(70%6*5& C%-(-: >7()$621%/6*5F: &0//1< 0$&25(: >5*1(5(1&

+- J(97>58;>D687A3 0(A%*1( 1%

*- !3 /281(&

B- 48DE? 7>;>D687A3 0(A%*1( 1*0%6(*- M! R G3 7(6*5 4*&2$5*1$7(;- M+3 >7()$621%/6*5 C6(74( (6A%6=F9 &0//1< 0$&25(2- MN3 ;7*%6

E- *=8FD687A3 0(A%*1( 1


9/130Z!"#$%

M- &:7D687A3 0(A%*1( 1D6 7>;>D687A3 0(A%*1( 11/7&

\- (:687>;>D687A C>7()$621%/6*5F!- '*68 /@ 1


10/130!_!"#$%

211C $>K:FE6 ;E79? PB AB?DE6=>66?A

,- '>E76

!- &E7EAB?DE6=>6FA

!- 3B?DE6=>6*0%6(7=%2F*- D(*758 *55 4*&2$5*7 ;(A&

;- .L(5(1*5 0$&25( CA%5*1%/69 26


11/130!!!"#$%

2111C $>;>D687A E59 7@E61/7& @/7 11/7& 0*8 ;( >7(&(61 (4(6 15(3 4*&2$5*7 (6A/1*7*&80>*11/7& *7( >7(&(61*6A 1/6A 1/ *A0%6%&1(7(A 0$&2*7%6%2 *=/6%&1&-

E- '*68 A7$=& *7( A(&%=6(A 1/ 0%0%2: ;5/2L /7 0/A%@8 1


12/130!+!"#$%

1UC 3>F>;6>9 >QQ>;6A 8Q AB?DE6=>66;6A W=>5 E;69C

0EPF> NC

"QQ>;687

!87E97>5>7K7@>AX

3B?DE6=>6%F E/6&17%21

U61(&1%6( C(61(7%26(74/$& &8&1(0F

M(27(*&( 1/6( *6A 0/1%5%18 U627(*&( 1/6( *6A 0/1%5%18

?5//A 4(&&(5& T*&/2/6&17%21%/6 T*&/A%5*1%/6 C&L(5(1*59 &80>*1


13/130

!B!"#$%

,D. KVK.

6'53*

;3*-$#. :.-13-* ("##$% "'()*+=

!5%30)$+. :)3.)'*-. ("##$% "'()*+=

6#($E-0E*3#03)5-.-(7"5-$%+$3) 0+'.#0:)%#*30+.E3)=:"'()-.303) .+)+5$#.(=

6#($E-0E*3#03)(7"5-$%+$3) 0+'.#0:0#.-1.+0+.E3)=

:-1.+0#)+5$#.(=


14/130

!G!"#$%

!"#$%&'()%* ,"-(.-*#$#)/ 0 1 00

"#$%&'#()'*+$ ,"#(- .$'$/0$ ,1)%2'*03 %)4*+-

"#$%&'#()'*+$0%$./0$ ,"5(6- ,#()'*+$0%$./0$ *+(*1*%).0 02#( /0

2#&'3'4%$ 1 4/(%2#56%).%&'-

"#( .$#$7%).0

8 +*#)%*+*# /9)+*0%0 ,+*#)%*+$-

8 +*#)%*+*# /+%/9)+*0%0 ,57**%&/$*"#$%&' : -6(-*7(%7.- ;

0


15/130

!N!"#$%

\$621%/6*5 25*&&%@%2*1%/6 ;*&(A

/6

17*6&0%11(7

DK c 6/7R*A7(6(7=%2

,E< c ;=8F7K


16/130

!Q!"#$%

K6A/27%6( &8&1(03 ;5//A ;/76( 2(2%@%27(&>/6&(& A$( 1/ 1%&&$(R&>(2%@%2 (H>7(&&%/6 /@

&>(2%@%2 7(2(>1/7&

ffffffffffffffffffffffffffffff

E


17/130

!X!"#$%

5()'*+$.9*# ?(/.3/#)')9& @ : @@

$+/#*+-


18/130

!Y

(*= 7>F>EA>

"5(C

• D&+%($0*A$= *+ +$.E$ %$.3*+/'0 : 01/7(A%6 &86*>1%2 4(&%25(&

• S(5(*&(A %61/ &86*>1%2 25(@1 ;8 >7/1(%6R 2/$>5(A C.D,SKF @$&%/6 /@ 4(&%25(&

O%1< 17(R&86*>1%2 0(0;7*6(

• S(5(*&(A ,E< %& 7*>%A58


19/130

!Z!"#$%

\/70*1%/6 /@ .D,SK 2/0>5(H

C&86*>1/;7(4%6: .D,JR+N h

&861*H%6F

7(d$%7(A @/7 @$&%/6 /@ ,E< =7*6$5(&

O%1< 0(0;7*6(

P86:F 3!($"

D786>@>56 67E5A?7

7>F>EA> – C6/1 &>(2%@%2 @/7

2


20/130

+_!"#$%

A%@@(7(61 &(7/18>(& /@ ;/1$5%&0

(A→G) cleave different SNARE

2/0>/6(61&

>7(4(61& *A7(6(7=%2 h

2*7*&80>- h

&/0*1%2F 17*6&0%11(7 7(5(*&(

3>786BD> ( ;8??85FB

;6>9

HT EFA8 E@EI

K@@(21& 5*&1 iB 0/61K>5>7E6D>59>56 85

5>7@> 7>JAD78:6


21/130

+!!"#$%

/4( EDD78@>9 :A>A Q87 P86:F*&1%2%18

@*2%*5 &L%6 O7%6L5(&

urinary incontinence due to “overactive bladder” (multiple site injections into

A(17$&/7 /@ ;5*AA(7 O%1< 4%&$*5%g*1%/6 $&%6= 28&1/&2/>8F

$6R2//7A%6*1(A (8( *5%=60(61 C&17*&;%&0$&F

$62/617/55(A ;5%6L%6= /@ (8(5%A& C;5(>*&0F ffffffffffffffffffffffffffffffffffffffffff

2


22/130

++!"#$%

P86:F786BD> ( HT8J08Z]I 68Z7/>7%*1( &L(5(1*5 0$&25( >*7*58&%&

R (H- $6(4(6 &0%5( /7 (8(5%A 2/617/5: A%@@%2$518 &O*55/O%6=:$7%6*78 7(1(61%/6

R*55(7=%2 7(*21%/6& h >/&&%;5( A(27(*&(A &(6&%1%4%18 O%1< 7(>(1%1%/$&

18 A$( 1/ %00$6( 7(&>/6&(

R7(A$2(A (0/1%/6*5 &(6&%1%4%18 h 2/=6%1%/6

C4%* %0>*%7(A @*2%*5 0$&25( &%=6*5%6= 1/ ;7*%6PF

Rhoney contraindicated in infants ≤ 1 year of age

R %6&$@@%2%(61 E- ;/1$5%6$0 %6>/71


23/130

+B

/E6> 8Q (;= 7>F>EA>G E;>6BF;=8FA6>7EA>

H(*="I• !"#"$%"& ()* +% ,$-+. *.&,/#.0"&123456 %"78 9.

$7":.#7*/#+;"%:",$%" 1()*,/;%? &+EE>%"&+%:,+9>:+/; /E ()*< 1-,"@ D -/%:@%.;$-:+7 6"69,$;"%8

• !"#$ &'#&(&)*+, -,./ )#.+01.-)&20334 E/, (#0*"+6",F%Cglaucoma, myasthenia gravis, ↑GI & bladder motility,+;%"7:+7+&"% D $% 7*"6+7$# G$,E$," $H";:%

• 9>:.,.# ()*< 1-%">&/7*/#+;"%:",$%"8 $9%";: E,/6;">,/;%C %.;:*"%+0"& +; #+I", D E/>;& +; 9#//&3

5.',&)&6. )* !"#$ &'#&(&)*+, 7 -,./ 0, 0 10+08.).+

)* 0,,.,, 1*&,*'&'9 (4 !"#$ &'#&(&)*+,


24/130

+G

!"#$%$&'"#

("#

()""#

$

)

)#

""#$

)

)

!"#$ & !"#$ '

!"#$%$&'"#

("#

()# (

+,-.,-/ 0-12 20123+1-/ 0-12 +,-.,-/ 0-12 20123+1-/ 0-12

)#(

"#$")#

)

)#

!"#$ )

+,-.,-/ 0-12 20123+1-/ 0-12

'B978FBA6BF;=8FA6>7EA> H(*="I

,E;7A W5>67E6


25/130

+N!"#$%

0=7>> ;FEAA>A 8Q (*="


26/130

+Q!"#$%

?"'(-4'76%* 75'5 #: *"#$%&'56'(-5' %&"%8%6#(5

• Alzheimer’s Disease

• 08*&1(6 *6=5( =5*$2/0* C5/2*5 *>>5%2*1%/6F


27/130

+X!"#$%

F(& / #()'*+$0%$./0$ *+(*1*%). ,=)+$A$7*' ). %/#.*+$-

>). Alzheimer’s DiseaseG

8 early signs of ↓ memory & ↓ cognition associated with ')00 )> #()'*+$.9*# >*1$.0 *+ #).%$4B (*77)#/3720

/+= +2#'$20 1/0/'*0

8 #(/./#%$.*0%*# 0*=$ $>>$#%0 )> 5HD 7$+$%./%*+9/+%*8#()'*+$.9*# =.290 *+ )%($.I*0$ +).3/' *+=*E*=2/'0

are: ↓ memory & ↓ cognition


28/130

+Y!"#$%

(*=" inhibitors for Alzheimer’s Disease

985>M>D1jF h 1*27%6( CE/=6(HjF

7(4(7&%;5( C&M>D7(@(77(A 18F


29/130

+Z!"#$%

@-6%#&-$' :#(

=*0$/0$ *0 =2$ %) /2%)8*332+*%& ; %($ +*#)%*+*#"5( .$#$7%). )+ 0


30/130

B_!"#$%

"978D=85


31/130

B!!"#$%

>7(R 4&- >/&1 (A7/>


32/130

B+!"#$%

156>7?>9 E;6@>7A

7(@(77(A 1/ 6(/&1%=0%6( @/7 08*&1/1(61: 5/6=(7 A$7*1%/6 CQ


33/130

BB!"#$%

“open angle glaucoma”

8 .$=2#%*)+ *+ *+%./8ocular pressure by ↑ contraction of #*'*/.& muscle & ↑ aqueous humor out8>')I

8 %)7*#/' ,#)+J2+#%*E/- '*#6"%#4"-6' ,')+9 /#%*+9- =/*'&

8 7)%$+%*/' >). 0&0%$3*# $>>$#%0

“narrow angle glaucoma”

8 0().%8%$.3 =.29 – induced constriction of pupil → stretching iris → relieved

1')# 07)+9$8'*


34/130

BG!"#$%

W1


35/130

BN!"#$%

F(& :$-**%2 4-(-$/5%5 ,./%($. %(/+ %$%/+&- I*%( 020%/*+$=

=$7)'/.*A$= 0 3$31./+$B

8 .$81*+=*+9 )> "#( %) .$#$7%).

8 +$I /#%*)+ 7)%$+%*/'

0 < < < Q ( F = F< H(*="I


36/130

BQ

08Z7EA> H(*="I

15=3 0%/&%&: ;5/2L /@ *22/00/A*1%/6 C6(*7 4&-

@*7FAEF


37/130

BX!"#$%

J7(4(61%/6a7(4(7&*5 /@ /7=*6/>56(55*61& h 2/0;$&1(A /7=*6/>(6(17*1%/6 O%1<

&17(&& %6 *6%0*5 0/A(5&F


38/130

BY!"#$%

J7(4(61%/6a7(4(7&*5 /@ /7=*6/>


39/130

BZ!"#$%

"#$%&'#()'*+$ ,"#(- .$'$/0$ ,1)%2'*03 %)4*+-

"#$%&'#()'*+$0%$./0$ ,"5(6- ,#()'*+$0%$./0$

*+(*1*%).0 02#( /0 =)+$A$7*' : 7&.*=)0%*93*+$-


40/130

G_!"#$%

E?3

J7(R=*6=5%/6%2 &86*>&(

5

R *=/6%&1 c 6%2/1%6(

R *61*=/6%&1 c 2$7*7(


41/130

G!

(*= $>;>D687AG !1/7 %& * D* %/6 2*1%/6 C6/1&/ @/7 0$&2*7%6%2F

• D* %/6& (61(7 *6A A(>/5*7%g(

• D%2/1%6%2 7(2(>1/7& 5/2*1(A /6 6(74( CDDF*6A &L(5(1*5 0$&25( CD'F

• 3 8Q


42/130

G+!"#$%

E


43/130

GB!"#$%

D%2/1%6(

O(55 *;&/7;(A @7/0 /7*5 2*4%18 C25(*&$7(a7(O*7A CA/>*0%6(F

R increased respiration (lethal effects via ↓ respiration)

R 6*$&(*a4/0%1%6= C21/7 17%==(7 g/6(

h 4*=*5 *@@(7(61&F

ET.3

R %627(*&(A ^S h ?J C&80>*1*7*&80>*1


44/130

GG!"#$%

“while there are many casual users of alcohol & cocaine,

>$I *+=*E*=2/'0 I() 03)


45/130

GN!"#$%

?(/.3/#)')9*#/' %($./7& )> +*#)%*+$ =$7$+=$+#$C

8+*#)%*+$ #)+%/*+*+9 923 ). %./+0=$.3/' 7/%#(

8#)+0%/+% 5HD "5( receptor stimulation to reduce “high” &3*+*3*A$ I*%(=./I/' 0&37%)30

8 E/.$+*#'*+$ ,5(/+%*4N-

8 7/.%*/' /9)+*0% ; "5( .$#$7%). ,0218)7%*3/' +*#)%*+$ $>>$#%0 /')+$

: /+%/9)+*03 )> $4)9$+)20 +*#)%*+$-

8 127.)7*)+ ,O&1/+N : F$''12%.*+N-

8 /+%*8depressant that ↑ dopamine & +).$7*+$7(.*+$ 1& 1')#


46/130

GQ!"#$%

.L(5(1*5 0$&25( (6A>5*1(

C6%2/1%6%2 7(2(>1/7F

;5/2L%6= A7$=&

R 6/6RA(>/5*7%g%6= C2/0>(1%1%4(F

R A(>/5*7%g%6=


47/130

GX!"#$%

D%2/1%6%2 S(2(>1/7& h D($7/0$&2$5*7 ?5/2L%6= M7$=&3

!85J9>D8FE71/7 /6 &L(5(1*5 0$&25(F

C$5(&3 (@@(21& 2*6 ;( 7(4(7&(A ;8 ,E(2$7/6%$0 h 7/2$7/6%$0

4>D8FE7A6=>6A


48/130

GY!"#$%

!85J9>D8FE71/7 /6 &L(5(1*5

0$&25(F

I$;/2$7*7%6( O*& >7/1/18>(

R &*0>5(& /@ >/%&/6 A*71& $&(A ;8 .- ,0(7%2*6& &1$A%(A %6!Q1(6(17*1%/6

D(O(7 A7$=& %6 1


49/130

GZ!"#$%

E "5(

83).$ 0%/1'$ *+%$./#%*)+ I*%( .$#$7%). ,(*9( />>*+*%&

: ('5%56-&6 6#


50/130

N_!"#$%

D2##*+&'#()'*+$ ?(/0$ @ E0P ?(/0$ @@ 1')#/0#*#2'/%*)+ ,=$7)'/.*A/%*)+-B %($+ >'/##*= 7/./'&0*0 *+ Q8R 3*+P

D*+9'$ =)0$ ,*PE- $>>$#% ; Q8R 3*+P %($+ =*00*7/%$0 I*%(*+ QS 3*+P

,=*00)#*/%*)+ : =*>>20*)+-

?(/0$ @@CF*%( 32'%*7'$ ). (*9( =)0$0 3/& 7.)9.$00 %) .$87)'/.*A/%*)+ I*%(

characteristics of ↓ receptor sensitivity

,=*/9+)0$= *+ TU I*%( +$.E$ 0%*32'/%*)+-

V2./%*)+ )> .$#)E$.& >.)3 QR8WS 3*+

?/%*$+%0 I*%( 3&/0%($+*/ 9./E*0 3).$ .$0*0%/+% %) 02##*+&'#()'*+$ :

may progress directly to Phase II with ↑ single dose

.$22%68525*&0* (6A& /6 A(=7*A*1%/6


51/130

N!!"#$%

;8 DFEA?E [ =>DE6:98;=8FA6>7EA>

HD(*="I

%2*5 A(@%2%(628 %6 >,E


52/130

N+!"#$%

#%@( 1


53/130

NB

G6"'( 5%2' '::'*65

• !-(2%#B-5*7$-( ,(&7$.>$#%0 #/+ .$02'% *+ : 1./=/.=*/ ). /..&%(3*/ – #(*'=.$+ 3).$ 020#$7%*1'$-

• H75*$' 4-%&

• @+#.$/0$ *+%./)#2'/. 7.$002.$• @+#.$/0$ *+%./9/0%.*# 7.$002.$• @+#.$/0$ *+%./#./+*/' 7.$002.$

3:;;/5*7%g%6= 4& 2/0>(1%1%4( *61*=/6%&1& l &L(5(1*5


54/130

NG!"#$%

A(>/5*7%g%6= 4&- 2/0>(1%1%4( *61*=/6%&1& l &L(5(1*5

0$&25( 6%2/1%6%2 7(2(>1/7 3

E/0>(1%1%4( *61*=/6%&1 HE67E;:7


55/130

NN!"#$%

5()'*+$.9*# ?(/.3/#)')9&

"#$%&'#()'*+$ ,"#(- .$'$/0$ ,1)%2'*03 %)4*+-

"#$%&'#()'*+$0%$./0$ ,"5(6- ,#()'*+$0%$./0$ *+(*1*%).0

02#( /0 =)+$A$7*' : 7&.*=)0%*93*+$-


56/130

NQ

(*= $>;>D687AG ):A;E7D687A

• N &$;18>(& CXR17*6&0(0;7*6(RA/0*%6 25*&& /@

7(2(>1/7&F

• .1%0$5*1/78 C'!:'B h 'NF %6 >(7%>3

4%* ] >7/1(%6:


57/130

NX!"#$%

!&1 2/1(61%*558 5(17/A$21

%6 2(71*%6 0$&


58/130

NY!"#$%

(:6858?A6G 3


59/130

NZ!"#$%

H) #()'*+$.9*# *++$.E/%*)+ %)/.%$.*)'$0

K)I$E$.B >2+#%*)+/' 32#/.*+*#

.$#$7%).0 )+ $+=)%($'*23

"=3*+*0%./%*)+ )> "5( #/20$0

=*'/%*)+

,51FEZ


60/130

Q_!"#$%

K H I

\7/0 \$72


61/130

Q!

!"##$% "'()*+ *,-+.

/01#$%+*2,* )+** *,-+.

3'"+0

/01#$%+*2'"

!"##$% 4'()*+

45

67

D/;(5 J7%g( %6 !ZZY 1/ \$72 )5$5/? 7%&) %#$'& @ABC (5 ,--&;#,(& ,$:#$,


62/130

Q+!"#$%

.8&1(0%2 *A0%6%&17*1%/6 /@ * 0$&2*7%6%2 *=/6%&1 *21& /6 *55 /@ >*7*&80>*1


63/130

QB!"#$%

*87> Y58WF>9K>G

M7$=& *@@(21%6= #"-24#"2'& *521%"#.4%* $2"# /1(61%*5 (@@(21& /6

&8&1(0& C>*7*&80>*1


64/130

QG

*8?DE7


65/130

QN!"#$%

?(1


66/130

QQ

B D

EK856=E5>;=8FI

*E79?G

• I*=$07.$/= E/0)=*'/%*)+ =2$ %) .$'$/0$ )> +*%.*# )4*=$ >.)3 %($E/0#2'/. $+=)%($'*23P – 5/ORA/&(3 7>QF>Z ↑HR due to sympathetic reflex in

7(&>/6&( 1/ A%5*1%/6 /@ 4*&2$5*1$7(- –


67/130

QX

B D

EK856=E5>;=8FI

$>AD?G• ;7/62


68/130

QY!"#$%

I($1%2 $&(& /@ 0$&2*7%6%2 *=/6%&1&3

D/1( 1;


69/130

QZ!"#$%

I($1%2 $&(& /@ 2/&1R/> *;A/0%6*5 A%&1(6&%/6: =*&17%2 *1/68F3

R *A0%6%&1(7 ;(1 7(1(61%/6: A8&@$621%/6*5 A(17$&/7a&>


70/130

X_!"#$%

T2%'*+$C 5()'*+$.9*# ?(/.3/#)')9&

"#$%&'#()'*+$ ,"#(- .$'$/0$ ,1)%2'*03 %)4*+-

"#$%&'#()'*+$0%$./0$ ,"5(6- ,#()'*+$0%$./0$

*+(*1*%).0 02#( /0 =)+$A$7*' : 7&.*=)0%*93*+$-


71/130

I($1%2 $&(& /@ 0$&2*7%6%2 *61*=/6%&1& C2/0>(1%1%4(F


72/130

X+!"#$%

> = C > F

C*55 /7*558 *21%4( (H2(>1 1%/17/>%$09 6/6( *7( (61%7(58 /7=*6 &8&1(0 &(5(21%4(F3

E678D3 /7*5: &-2: %-0- /7 %-4- C(7


73/130

XB!"#$%

I($1%2 $&(& /@ 0$&2*7%6%2 *61*=/6%&1& C2/0>(1%1%4(F

9E75E;%6( C>*71%*5 &(5(21%4%18 @/7 %61(&1%6*5 =*6=5%*9 $&(A @/7 ]U

$52(7& 1/ A(27(*&( >7/1(/581%2 (6g80( &(27(1%/6F

17%%6( h A%>


74/130

XG

3 &7>98? "QQ>;6 8Q ,E5KF*1/&1$7*5 /1(6&%/6

4(%6& &80>*1*1*1*7*&80>*1*1*12


75/130

XN!"#$%

"%.)7*+$ ,/+%*8320#/.*+*#- %)4*#*%&C

2(/ -5 - 8#&'9 "#6 -5 - "-('9 ('2 -5 - 8''69 8$%&2 -5 - 8-69.-2 -5 - "-66'( 1 :7$$ -5 - :$-5F

#(

“hot, dry, red & mad”

(*9( =)0$0 )> /%.)7*+$ #/+ $+%$. %($ 5HD : *+*%*/''& #/20$ '>*%6-6%#&

,.$0%'$00+$00B (/''2#*+/%*)+0B =$'*.*23-B %($+ 7.)9.$00 %) 2'4('55%#&

,#/.=*/#B .$07*./%*)+B #)3/B =$/%(-

E*$1%/6&a E/617*%6A%2*1%/6& O%1< *61%R0$&2*7%6%2& C%&&$( /@ 5*2L /@ /7=*6


76/130

XQ!"#$%

E*$1%/6& a E/617*%6A%2*1%/6& O%1< *61% 0$&2*7%6%2& C%&&$( /@ 5*2L /@ /7=*6

&>(2%@%2%18F

J !E778W E5KF> KFE:;8?E due to ↑ increased intraR/2$5*7 >7(&&$7( h 0*8>7(2%>%1*1( *11*2L& %6 >7(A%&>/&(A – $&( %& Wm %6 />(6 *6=5(

R "Z6>75EF =>E6 87 Q>@>7

R *E79A8D=EK


77/130

XX!"#$%

&=E7?E;8F8KB 8Q !87E97>5>7K /@ 6($7/17*6&0%11(7K- (;6


78/130

XY!"#$%

11C (7;=;6:7>L AB56=>AL 7>F>EA> E59 >QQ>;687 ;>FF E;6


79/130

XZ!"#$%

/ OC

T',I

T',I c 4(&%2$5*7 0/6/*0%6(17*6&>/71(7

D/7(>%6(>%6(>*0%6(

*7( ;E6>;=8FE?AG,F

,F

B,G


80/130

Y_!"#$%

/ RC

,F


81/130

Y!!"#$%

/ cC

.D,J. c &86*>1/&/0(R*&&/2%*1(A >7/1(%6&

T,'J. c 4(&%25(R*&&/2%*1(A0(0;7*6( >7/1(%6&

.D,J.

T,'J.


82/130

Y+!"#$%

/ SC

DKI DKI c 6/7(>%6(>/71(7

T',IT',I c 4(&%2$5*7 0/6*0%6(

17*6&>/71(7

111C 4>A67:;66EP8F;=8FJ%J?>6=BF 67E5AQ>7EA> H*%)0I

!- .>(2%@%2 @/7 2*1(2


83/130

YB!"#$%

+- WR0(17/H%0*1(58 !__R@/5A-N- E,F

F,

,F

F2,I

2 B2

2 B2

?- )858E? 8Z H)(%I !- D/1 4(78 &>(2%@%29 0(1*;/5%g(& 0*68 18>(& /@ *0%6(& C(-=-: NR^IF

+- S(0/4(& 1


84/130

YG!"#$%

/ eC

*$+,#$-.+,#

/#"0,#$-.+,#

12.#$+,#$-.+,#

34

4313

43

53)

34

43

43

13'

34

43

13

453 )

53)

)67 8+-9:.2;9 ?>+: 12.


85/130

YN!"#$%

/ fC

;#5-"30+

;3%71.#J75%+07*-)+$3)


86/130

YQ!"#$%

0EPF> NC

(K>56 36>D "QQ>;6 )>;=E57(&&*61&

I(70%6*1%/6 J/1(61%*1(& DK ?5/2L& DKI

S(&(7>%6( .1/7*=(M(>5(1(& DK C*6A

A/>*0%6(F?5/2L& 4(&%2$5*7 *21%4(

17*6&>/71 CT',IF

?7(185%$0: =$*6(1/6&(& .1%0$5*1( &%=6*5 17*6&A$21%/6

R *6A R,A7(6/2(>1/7*61*=/6%&1&

S(2(>1/7 U61/7 ;5/2L*A(

]5$2/2/71%2/%A& I(70%6*1%/6 J/1(61%*1( K>% U61*L(


87/130

YX!"#$%

/ N^C


88/130

YY!"#$%

/ NNC


89/130

YZ!"#$%

/ NOC


90/130

Z_!"#$%

/ NRC


91/130

Z!!"#$%

/ NcC


92/130

Z+!"#$%

/ NSC

12C "QQ>;6A 8Q D=E7?E;8F8K56A 85 587E97>5>7K:7867E5A?


93/130

ZB!"#$%

0EPF> NC

(K>56 36>D "QQ>;6 )>;=E57(&&*61&

I(70%6*1%/6 J/1(61%*1(& DK ?5/2L& DKI

S(&(7>%6( .1/7*=( M(>5(1(& DK C*6A M,F?5/2L& 4(&%2$5*7 *21%4(

17*6&>/71 CT',IF

?7(185%$0: =$*6(1/6&(& .1%0$5*1( &%=6*5 17*6&A$21%/6

R *6A R,A7(6/2(>1/7*61*=/6%&1&

S(2(>1/7 U61/7 ;5/2L*A(

]5$2/2/71%2/%A& I(70%6*1%/6 J/1(61%*1( K>% U61*L(


94/130

ZG

&=E7?E;8F8KB 8Q (97>58;>D687A

1C (97>58;>D687A

,- Receptors which are activated by “sympathomimetic amines” and “catecholamines”

!- 3B?DE6=8?6%6(>%F

;- D/7(>%6(>*0%6( CM,F +- *E6>;=8FE?A

*- E/$6A& 2/61*%6%6= * 2*1(21/7& *7( 5*7=(: XR17*6&0(0;7*6( &>*66%6= 7(2(>1/7&

!- ]R>7/1(%6 2/$>5(A 7(2(>1/7& C]JESF

*- U61(7*21 O%1< (6A/=(6/$& *=/6%&1&3 K>%: DK *6A M, +- ,A7(6/2(>1/7 *=/6%&1 A7$=& 0%0%2 1


95/130

ZN!"#$%

E- I8>(& /@ *A7(6/2(>1/7& *6A &$;18>(&

!- ,5>1/7&*- Epi ≥ NE >> Iso (Iso is isoproterenol, a synthetic catecholamine)

;- I(& /@ R7(2(>1/7&

%- !

%%- +

2- I(& /@ !R7(2(>1/7& C,: ?: *6A MF

A- I(& /@ +R7(2(>1/7& C,: ?: *6A EF

+- ?(1* CF 7(2(>1/7&*- Iso > Epi ≥ NE

;- I(& /@ R7(2(>1/7&

%- !3 K>% c DK

%%- +3 K>% o DK

%%%- B3 U&/ c DK o K>%B- M, 7(2(>1/7&

*- I(& /@ M, 7(2(>1/7& CM! R MNF

;- M, *5&/ &1%0$5*1(& !R7(2(>1/7&


96/130

ZQ!"#$%

11C "QQ>;6A 8Q E;658;>D687A ,- ,21%/6& /@ 2*1(2*1


97/130

ZX!"#$%

?- ](6(7*5%g*1%/6& CI*;5( ! &1%/6&F !- '/&1 2*7A%*2 (@@(21&3 !

+- '/&1 &0//1< 0$&25( 2/617*21%5( (@@(21&3

!

B- '/&1 &0//1< 0$&25( 7(5*H*61 (@@(21&3 +

G- '/&1 0(1*;/5%2 (@@(21&3 +

N- '/&1 >7()$621%/6*5 (@@(21&3 +

Q- '*68 %6


98/130

ZY!"#$%

E- J7()$621%/6*5 C>7(&86*>1%2F 7(2(>1/7&3 + : : *6A M+

/ NC

111C "QQ>;6A 8Q AB?DE6=8?6;=8FE?A ;E79? ,- M%7(21 (@@(21& /6 1/5*7%g*1%/6


99/130

ZZ!"#$%

*- U627(*&( >/5*7%g*1%/6;- U627(*&( >/5*7%g*1%/6

/ OC

+- W1%2F >*2(0*L(7&%%- .


100/130

!__!"#$%

?- M%7(21 (@@(21& /6 4*&2$5*7 ;(A&

!- DK3 !: +: ! +- K>%3 !: +: !: +

B- U&/3 !: +

0EPF> OC $>AD85A>A 8Q @EA;:FE7 P>9A

2EA;:FE7 P>9 $>;>D687A "D< !" 1A8 4(

.L%6 !: + E/6&17%21%/6 E/6&17%21%/6 D/6( R

.>5*62(6A(61


101/130

!_!!"#$%

UT- 4>6>7?E5 E76>7AA:7>: “Hydraulic equation”

/ RC

2-.13-)#'$5'$

>#$-*5+.35%+.-*.+(3($-0)+


102/130

!_+!"#$%

2C 15QF:>5;> 8Q 6=> AB?DE6=>667@8:A ABA6>?A 85 PF889D7>AA:7>

/ cC

21C $8F> 8Q 6=> PE787>;>D687 7>QF>Z 8A6E6K:FE6AA:7> ,- .17(12< 7(2(>1/7&

!- E*7/1%A &%6$& *6A */71%2 *72<+- ↑ ?J &17(12


103/130

!_B!"#$%

B- ↑ \%7%6= /@ *@@(7(61& 1/ 1*1A 68 AB?DE6=8?6;=8FE?A

,- S(&>/6&(& 1/ %-4- ;/5$& %6)(21%/6 C! =aL=F


104/130

!_G!"#$%C\7/0 17/1(7(6/5 C* ! e + *=/6%&1F

K>%6(>


105/130

!_N!"#$%

?- S(&>/6&(& 1/ %-4- %6@$&%/6

D/7(>%6(>7/1(7(6/5 K>%6(>


106/130

!_Q!"#$%

E- .$00*78 /@ %6@$&%/6 (@@(21&

0EPF> RC *E79QQ>;6A 8Q 58;>D687 EK85% ↑↑ ↑↑b ↓↓b ↓b ↓b ↑ ↑ ↑ ↑

JK ↑↑ ↑↑ ↑ ↑↑ ↑↑ ↑↑ ↓ _:↓:↑ _:↓:↑

bM/&(RA(>(6A(61

2111C 31/7&


107/130

!_X!"#$%

/ _C


108/130

!_Y!"#$%

?- !R,A7(6/2(>1/7&

/ dC


109/130

!_Z!"#$%

E- +R,A7(6/2(>1/7&

/ eC

E(55 *21%4*1%/6

E(55 %658;>D687 (56EK8577EF ABA6>?A PB E97>58;>D687A

/ NC


110/130

!!_!"#$%

K: >

>6N

6N

BCN+*+-(+

,- I5*%6(A 5*7=(58 @7/0 L6/O5(A=( /@ 1/6&(& (5%2%1(A ;8 R *6A R*A7(6/2(>1/7*=/6%&1& %6 1


111/130

!!!!"#$%

:..5,$5/%0& !

B"*.#0- *2"-'*$%2" 7#12*%$, !

.0//1<

0$&25(

C0&2*2"&$.%*$%2" 60.$#.%21#&> ).#3*0)%110., &)5%"*$#.> 7#%"&9 !: &/0( +

C0&2-%10$%2" 6&D#1#$01 0"- 7%&*#.01 8#-&9 +

U61(&1%6*5 7(5*H*1%/63 J7(&86*>1%2 A(27(*&( ,E< 7(5(*&(

S(5*H*1%/6 /@ &0//1< 0$&25(

+

+

]-U- &>


112/130

111C J(97>58;>D687 E56EK85 RC "QQ>;6A 8Q JE97>58;>D687 E56EK85


113/130

!!B!"#$%

,5@$g/&%6 C`7/[*17*5F

,61*=/6%&0 D/6(d$%5%;7%$02/0>(1%1%4(

Kd$%5%;7%$0 2/0>(1%1%4( Kd$%5%;7%$0 2/0>(1%1%4(

M$7*1%/6 /@*21%/6

#/6= CA*8&F '/A(7*1( C


114/130

!!G!"#$%

,- 0E?A:F8A1/7& %6 >7/&1*1( &0//1< 0$&25(;- !?R *6A !MR7(2(>1/7& *7( %0>/71*61 %6 4*&2$5*7 &0//1< 0$&25(9 1


115/130

!!N!"#$%

B#."-*

G

BC BC

Q4.+)+5$#.

Q4.+)+5$#.

6%+0$#*-"30+ K*#)D-1+

G

BC BC

Q4.+)+5$#.

Q4.+)+5$#.

6, 6,

>-)%7)-.13-

6.-R#(30 K*#)D-1+

G

BC BC

Q4.+)+5$#.

Q4.+)+5$#.

6N


116/130

!!Q!"#$%

2C *E79QQ>;6A 8Q D=>568FE? 85 >DD=7J9 7>AD85A>AG“>DD=7 7>@>7AEF”

K*##15.+(('.+

,+-.$ N-$+

QISTUSQGUTSV

QISTWV QXVTUG

QGSTUS

QVVTIS

QXV GVV

QUV GQV

QWV GQV

QYSTQQV

C530+5%.30+ -A$+. 5%+0$#*-"30+

C530+5%.30+ ?+A#.+ 5%+0$#*-"30+

6%+0$#*-"30+

QWVTQGZK*##15.+(('.+

,+-.$ N-$+

K*##15.+(('.+

,+-.$ N-$+

,A*>1(A @7/0 ^/@@0*6: ?-?- %6 m*1g$6=D E,%#' ,$) 1-#$#',- F*,/+,'5-5:9 : >-!G_-


117/130

!!X!"#$%

21C &=E7?E;8F8K76A 8Q >7K86 EFYEF8*71$0 *&0 p/@@ 5*;(5qF

?- K@@(21&!- I /@ *5L*5/%A& 5(H >/&1R>*71$0 /&1R>*71$0 58;>D687 (56EK85


118/130

!!Y!"#$%

1C *85678F 8Q ?E\87 D>77EF ABA6>?A PB E97>58;>D687A

/ NC

>6N

6N

BCN+*+-(+

,- I5*%6(A 5*7=(58 @7/0 L6/O5(A=( /@ 1/6&(& (5%2%1(A ;8 R *6A R*A7(6/2(>1/7&%6 1


119/130

!!Z!"#$%

, !

B"*.#0- *2"-'*$%2" 7#12*%$, !

.0//1<0$&25(

C0&2*2"&$.%*$%2" 60.$#.%21#&> ).#3*0)%110., &)5%"*$#.>7#%"&9

!: &/0( +

C0&2-%10$%2" 6&D#1#$01 0"- 7%&*#.01 8#-&9 +

U61(&1%6*5 7(5*H*1%/63 J7(&86*>1%2 A(27(*&( ,E< 7(5(*&(S(5*H*1%/6 /@ &0//1< 0$&25(

+ +

]-U- &>


120/130

!+_!"#$%

0EPF> O

,61*=/6%&1

! + ! + .(5(21%4%18

J7/5/5 T(78 5/O T(78 5/O ^%=


121/130

!+!!"#$%

111C 47A> E;658;>D687 E56EK85


122/130

!++!"#$%

12C !85JA>F>;6 JE97>58;>D687 E56EK857>58F C&*7%&/69 %1 %& *6 *=/6%&1F

/ OC

,F2,I

F,2,I

,B,

F,

?- &78D7E58F8F CU6A(7*5F

!- ?$5L /6 11/7&+- BRE*7;/6 2(71%(&

B- D/1( 17(&(62( /@ 17/>7*6/5/5 *6A &/0( R;5/2L(7&B- D($17*5 *61*=/6%&1G- .1*;%5%g(& 2*7A%*2 0(0;7*6(& %6


123/130

!+B!"#$%

E- !E98F8F CE/7=*7AF!- #/6=R*21%6=

+- U64(7&( *=/6%&1 *21%4%18B- U6A%2*1%/6&3 (71(6&%/6 *6A 08/2*7A%*5 %&2


124/130

!+G!"#$%

K- 0


125/130

!+N!"#$%

]- *E7@>9


126/130


127/130

!+X!"#$%

E- "A?8F8F C?7(4%;5/2F!- \*&1R*21%6=+- .


128/130

!+Y!"#$%

21C (K859 J(97>58;>D687 (56EK85 R

J7/>7*6/5/5 '(1/>7/5/5 #*;(1*5/5 J%6A/5/5

RS(2(>1/7 *61*=/6%&1 &(5(21%4%18 D/6( ! D/6( D/6(

,=/6%&1 *21%4%18 D/6( U64(7&( .5%=


129/130

!+Z!"#$%

E*7A%/4*&2$5*7 &8&1(0 E*7A%/4*&2$5*7

^(*71 T*&/2/6&17%21%/6 %6 &L(5(1*5 ;(A&

K5(217/>


130/130

B- ,77

Documents

Autonomic pharmacology question set